<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8FF77491-6D8F-46B3-A501-502C02F1142F"><gtr:id>8FF77491-6D8F-46B3-A501-502C02F1142F</gtr:id><gtr:name>Bristol Royal Infirmary</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2400BE3D-876A-41C9-8178-94887A51CA1C"><gtr:id>2400BE3D-876A-41C9-8178-94887A51CA1C</gtr:id><gtr:name>University Hospitals Birmingham NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Metchley Park Road</gtr:line1><gtr:city>Birmingham</gtr:city><gtr:postCode>B15 2PR</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/864A9845-BA2F-4BF8-AD6D-91B724CF5991"><gtr:id>864A9845-BA2F-4BF8-AD6D-91B724CF5991</gtr:id><gtr:name>Royal Infirmary of Edinburgh</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1170893-AEB7-4F2F-AA16-67D6E09D2608"><gtr:id>D1170893-AEB7-4F2F-AA16-67D6E09D2608</gtr:id><gtr:name>Glasgow Royal Infirmary</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AE6EAB1A-CC2F-4FDB-A57F-41E76D78ACAB"><gtr:id>AE6EAB1A-CC2F-4FDB-A57F-41E76D78ACAB</gtr:id><gtr:name>Oxford University Hospitals NHS Trust</gtr:name><gtr:address><gtr:line1>Churchill Site</gtr:line1><gtr:line2>Old Road</gtr:line2><gtr:line3>Headington</gtr:line3><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX3 7LJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7A601437-2EFC-42F2-9E23-3B4D475CF80D"><gtr:id>7A601437-2EFC-42F2-9E23-3B4D475CF80D</gtr:id><gtr:name>Gloucestershire Royal Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7035AE5D-F006-4762-9959-D965363291F6"><gtr:id>7035AE5D-F006-4762-9959-D965363291F6</gtr:id><gtr:name>Merck</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B525E1E8-5E37-4C23-B66D-6E6D79AC783A"><gtr:id>B525E1E8-5E37-4C23-B66D-6E6D79AC783A</gtr:id><gtr:name>Royal Devon and Exeter NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4E55B119-02E7-43F3-9B39-DD48A6511372"><gtr:id>4E55B119-02E7-43F3-9B39-DD48A6511372</gtr:id><gtr:name>Addenbrooke's Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DD1F1403-9928-4563-8E48-326ACF87C706"><gtr:id>DD1F1403-9928-4563-8E48-326ACF87C706</gtr:id><gtr:name>University Hospital of Wales</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:department>Medical Research Council</gtr:department><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8FF77491-6D8F-46B3-A501-502C02F1142F"><gtr:id>8FF77491-6D8F-46B3-A501-502C02F1142F</gtr:id><gtr:name>Bristol Royal Infirmary</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2400BE3D-876A-41C9-8178-94887A51CA1C"><gtr:id>2400BE3D-876A-41C9-8178-94887A51CA1C</gtr:id><gtr:name>University Hospitals Birmingham NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Metchley Park Road</gtr:line1><gtr:city>Birmingham</gtr:city><gtr:postCode>B15 2PR</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/864A9845-BA2F-4BF8-AD6D-91B724CF5991"><gtr:id>864A9845-BA2F-4BF8-AD6D-91B724CF5991</gtr:id><gtr:name>Royal Infirmary of Edinburgh</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1170893-AEB7-4F2F-AA16-67D6E09D2608"><gtr:id>D1170893-AEB7-4F2F-AA16-67D6E09D2608</gtr:id><gtr:name>Glasgow Royal Infirmary</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE6EAB1A-CC2F-4FDB-A57F-41E76D78ACAB"><gtr:id>AE6EAB1A-CC2F-4FDB-A57F-41E76D78ACAB</gtr:id><gtr:name>Oxford University Hospitals NHS Trust</gtr:name><gtr:address><gtr:line1>Churchill Site</gtr:line1><gtr:line2>Old Road</gtr:line2><gtr:line3>Headington</gtr:line3><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX3 7LJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7A601437-2EFC-42F2-9E23-3B4D475CF80D"><gtr:id>7A601437-2EFC-42F2-9E23-3B4D475CF80D</gtr:id><gtr:name>Gloucestershire Royal Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7035AE5D-F006-4762-9959-D965363291F6"><gtr:id>7035AE5D-F006-4762-9959-D965363291F6</gtr:id><gtr:name>Merck</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B525E1E8-5E37-4C23-B66D-6E6D79AC783A"><gtr:id>B525E1E8-5E37-4C23-B66D-6E6D79AC783A</gtr:id><gtr:name>Royal Devon and Exeter NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4E55B119-02E7-43F3-9B39-DD48A6511372"><gtr:id>4E55B119-02E7-43F3-9B39-DD48A6511372</gtr:id><gtr:name>Addenbrooke's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DD1F1403-9928-4563-8E48-326ACF87C706"><gtr:id>DD1F1403-9928-4563-8E48-326ACF87C706</gtr:id><gtr:name>University Hospital of Wales</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/F2372519-5455-4BEA-AD7C-D2CFB717485F"><gtr:id>F2372519-5455-4BEA-AD7C-D2CFB717485F</gtr:id><gtr:firstName>Damian</gtr:firstName><gtr:surname>McManus</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/BF3E2EE4-E95F-4EA8-B712-1A9C82B32B0C"><gtr:id>BF3E2EE4-E95F-4EA8-B712-1A9C82B32B0C</gtr:id><gtr:firstName>Liam</gtr:firstName><gtr:surname>Murray</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7EA7E476-F8CD-4A75-9746-0058BEC86C92"><gtr:id>7EA7E476-F8CD-4A75-9746-0058BEC86C92</gtr:id><gtr:firstName>Rebecca</gtr:firstName><gtr:surname>Fitzgerald</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/CDA8B82C-E414-4BDA-90CD-4D782AA1B045"><gtr:id>CDA8B82C-E414-4BDA-90CD-4D782AA1B045</gtr:id><gtr:firstName>Kevin</gtr:firstName><gtr:surname>Brindle</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2396B071-306D-4BA2-A29F-5AD0F5798337"><gtr:id>2396B071-306D-4BA2-A29F-5AD0F5798337</gtr:id><gtr:firstName>Laurence</gtr:firstName><gtr:surname>Lovat</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/747FD401-6708-4C8D-A7AB-22646AAACE17"><gtr:id>747FD401-6708-4C8D-A7AB-22646AAACE17</gtr:id><gtr:firstName>Marco</gtr:firstName><gtr:otherNames>Riccardo</gtr:otherNames><gtr:surname>Novelli</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/32D19AAE-572C-4FAF-A598-EB0B82DBAA54"><gtr:id>32D19AAE-572C-4FAF-A598-EB0B82DBAA54</gtr:id><gtr:firstName>Brian</gtr:firstName><gtr:surname>Johnston</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/394401C1-C341-430C-94DD-E1A559D63B64"><gtr:id>394401C1-C341-430C-94DD-E1A559D63B64</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:otherNames>Charles</gtr:otherNames><gtr:surname>Patterson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0601390"><gtr:id>DEDDD9DC-DD69-40E0-8A67-AE6289E73E70</gtr:id><gtr:title>Biomarker qualification in Barrett s oesophagus</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0601390</gtr:grantReference><gtr:abstractText>A type of oesophageal or gullet cancer, called adenocarcinoma, is rapidly increasing in the western world. Most patients do not seek medical attention until they develop swallowing difficulties and by then the cancer is usually advanced with a 5-year survival of 20%. However, if the cancer is detected early then the survival rate can be improved to 80%. These cancers usually develop as a complication of a condition called Barrett?s oesophagus. However, most people in the population with Barrett?s oesophagus will not develop cancer. Therefore research is needed to identify the patients at greatest risk for oesophageal cancer. In this grant we are testing some promising molecular tools to see whether they can predict cancer progression using a large clinical biopsy resource from the Northern Ireland Barrett s Oeospagus Register. If we could find a molecular test that predicted cancer development this would prevent many patients with Barrett s oeosphagus having unecessary endoscopy examinations and enable us to target resources to patients at highest risk.</gtr:abstractText><gtr:technicalSummary>Introduction: The incidence of oesophageal adenocarcinoma (OAC) is increasing dramatically in the west and has a very poor prognosis. Barrett?s oesophagus (BE) is an established risk factor for OAC. Currently, BE patients are offered regular endoscopy (surveillance) to detect cancerous changes early. This hinges on the subjective histopathological assessment of multiple, random biopsies which is problematic. Biomarkers have the potential to reduce sampling bias and improve the risk-stratification of patients. Since endoscopy is invasive, unpleasant and costly, ideally biomarkers should be developed for non-endoscopic applications. Biomarkers for this study have therefore been selected on the basis of their mechanistic role, abundance and ease of detection.
Hypothesis: Molecular biomarkers (aneuploidy, cyclin A, lectins) have the potential to risk stratify BE patients. In addition because these changes occur at the epithelial surface and are abundant there is the potential to develop these markers for cytological screening (aneuploidy, cyclin A) and for novel fluorescent endoscopic diagnostic methods (lectins). 
Aims: 1. Determine whether specific biomarkers can predict cancer risk in a highly characterised, population-based BE cohort. 2. Use biomarkers, appropriately qualified in phase 1, to develop: a) a quantitative assay for assessment of biomarker(s) from a cytological specimen, b) a lectin-probe suitable for fluorescence imaging detectable at endoscopy.
Study design: Phase 3 retrospective longitudinal repository study using a nested case-control approach within the N Ireland BE Register (NIBR). The NIBR includes every adult identified with BE within NI (population 1.7 million) between 1993-2005. Cases are 108 BE patients who have progressed to OAC or HGD, compared with 3 controls per patient (matched for age, sex and year of diagnosis) who have not progressed to these states; (OAC incidence 0.4% per year, HGD incidence 0.08% per year) from a total of 23,771 person years of follow-up. The expression of cyclin A (immunohistochemistry), lectins (HPA, PNA, WGA, CON-A), (fluorescence histochemistry) and aneuploidy (image cytometric analysis) will be determined in biopsies at specific time intervals. For the assay development, cytological samples (n=1000) will be taken from ongoing surveillance programmes in Cambridge, Belfast and UCLH. These patients are well characterised with longitudinal data over 5 years. This well established cohort affords our industrial partner GSK the opportunity to examine genetic aberrations in ERBB2 as a prelude to a clinical chemoprevention trial. 
Clinical benefit: The use of biomarkers will benefit patients with BE by enabling accurate assessment of cancer risk and providing reliable surrogate endpoints for intervention studies.</gtr:technicalSummary><gtr:fund><gtr:end>2010-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>527624</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bristol</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Clinical Sciences</gtr:department><gtr:description>OCCAMS (Oesophageal Cancer Clinical and Molecular Staging)</gtr:description><gtr:id>F2122604-E35D-43A7-9042-B637687840C7</gtr:id><gtr:impact>PMID: 19526624 
PMID: 20621683</gtr:impact><gtr:outcomeId>10993C9ABB4-6</gtr:outcomeId><gtr:partnerContribution>Shared dataShared dataShared dataShared dataShared dataShared dataShared dataShared dataShared dataShared data</gtr:partnerContribution><gtr:piContribution>We set up this UK multicentre collaboration which currently includes 10 centres from around the UK</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospital of Wales</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>OCCAMS (Oesophageal Cancer Clinical and Molecular Staging)</gtr:description><gtr:id>57B2A0D9-889B-4A20-AC2E-2994119B686C</gtr:id><gtr:impact>PMID: 19526624 
PMID: 20621683</gtr:impact><gtr:outcomeId>10993C9ABB4-8</gtr:outcomeId><gtr:partnerContribution>Shared dataShared dataShared dataShared dataShared dataShared dataShared dataShared dataShared dataShared data</gtr:partnerContribution><gtr:piContribution>We set up this UK multicentre collaboration which currently includes 10 centres from around the UK</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Addenbrooke's Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>OCCAMS (Oesophageal Cancer Clinical and Molecular Staging)</gtr:description><gtr:id>4D96191F-F88A-4470-A0F7-C56F01DD49CF</gtr:id><gtr:impact>PMID: 19526624 
PMID: 20621683</gtr:impact><gtr:outcomeId>10993C9ABB4-10</gtr:outcomeId><gtr:partnerContribution>Shared dataShared dataShared dataShared dataShared dataShared dataShared dataShared dataShared dataShared data</gtr:partnerContribution><gtr:piContribution>We set up this UK multicentre collaboration which currently includes 10 centres from around the UK</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Infirmary of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>OCCAMS (Oesophageal Cancer Clinical and Molecular Staging)</gtr:description><gtr:id>D6246399-7953-466D-9E11-EFEC86A75D4F</gtr:id><gtr:impact>PMID: 19526624 
PMID: 20621683</gtr:impact><gtr:outcomeId>10993C9ABB4-3</gtr:outcomeId><gtr:partnerContribution>Shared dataShared dataShared dataShared dataShared dataShared dataShared dataShared dataShared dataShared data</gtr:partnerContribution><gtr:piContribution>We set up this UK multicentre collaboration which currently includes 10 centres from around the UK</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospitals Birmingham NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>OCCAMS (Oesophageal Cancer Clinical and Molecular Staging)</gtr:description><gtr:id>F5C81121-2C3C-48D3-A7BA-7DC22EF7B79E</gtr:id><gtr:impact>PMID: 19526624 
PMID: 20621683</gtr:impact><gtr:outcomeId>10993C9ABB4-1</gtr:outcomeId><gtr:partnerContribution>Shared dataShared dataShared dataShared dataShared dataShared dataShared dataShared dataShared dataShared data</gtr:partnerContribution><gtr:piContribution>We set up this UK multicentre collaboration which currently includes 10 centres from around the UK</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gloucestershire Royal Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>OCCAMS (Oesophageal Cancer Clinical and Molecular Staging)</gtr:description><gtr:id>649EBB90-7BE6-4536-896C-1BDF7572A849</gtr:id><gtr:impact>PMID: 19526624 
PMID: 20621683</gtr:impact><gtr:outcomeId>10993C9ABB4-9</gtr:outcomeId><gtr:partnerContribution>Shared dataShared dataShared dataShared dataShared dataShared dataShared dataShared dataShared dataShared data</gtr:partnerContribution><gtr:piContribution>We set up this UK multicentre collaboration which currently includes 10 centres from around the UK</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Merck</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>prognostic gene signtaures in oesophageal cancer</gtr:description><gtr:id>C0A4C059-B685-4EC3-9624-8F7A47EF3FE4</gtr:id><gtr:impact>This profiling project would not have been affordable within the programme grant. The data has been invaluable for developing prognostic alogorithm which are now at the validation stage.</gtr:impact><gtr:outcomeId>E4B76902070-1</gtr:outcomeId><gtr:partnerContribution>Research data</gtr:partnerContribution><gtr:piContribution>Research on data provided</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Glasgow Royal Infirmary</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>OCCAMS (Oesophageal Cancer Clinical and Molecular Staging)</gtr:description><gtr:id>ABC7BF77-7432-4F24-A62C-4A14BE259C6E</gtr:id><gtr:impact>PMID: 19526624 
PMID: 20621683</gtr:impact><gtr:outcomeId>10993C9ABB4-5</gtr:outcomeId><gtr:partnerContribution>Shared dataShared dataShared dataShared dataShared dataShared dataShared dataShared dataShared dataShared data</gtr:partnerContribution><gtr:piContribution>We set up this UK multicentre collaboration which currently includes 10 centres from around the UK</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Devon and Exeter NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>OCCAMS (Oesophageal Cancer Clinical and Molecular Staging)</gtr:description><gtr:id>443493A3-4370-4211-964C-B22AFECFC7E4</gtr:id><gtr:impact>PMID: 19526624 
PMID: 20621683</gtr:impact><gtr:outcomeId>10993C9ABB4-4</gtr:outcomeId><gtr:partnerContribution>Shared dataShared dataShared dataShared dataShared dataShared dataShared dataShared dataShared dataShared data</gtr:partnerContribution><gtr:piContribution>We set up this UK multicentre collaboration which currently includes 10 centres from around the UK</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bristol Royal Infirmary</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>OCCAMS (Oesophageal Cancer Clinical and Molecular Staging)</gtr:description><gtr:id>63DAD5CE-7A1D-4CFD-A08A-2B62E891762E</gtr:id><gtr:impact>PMID: 19526624 
PMID: 20621683</gtr:impact><gtr:outcomeId>10993C9ABB4-2</gtr:outcomeId><gtr:partnerContribution>Shared dataShared dataShared dataShared dataShared dataShared dataShared dataShared dataShared dataShared data</gtr:partnerContribution><gtr:piContribution>We set up this UK multicentre collaboration which currently includes 10 centres from around the UK</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oxford University Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>OCCAMS (Oesophageal Cancer Clinical and Molecular Staging)</gtr:description><gtr:id>5EAEB13B-C154-4F07-9B2E-32972C45AC91</gtr:id><gtr:impact>PMID: 19526624 
PMID: 20621683</gtr:impact><gtr:outcomeId>10993C9ABB4-7</gtr:outcomeId><gtr:partnerContribution>Shared dataShared dataShared dataShared dataShared dataShared dataShared dataShared dataShared dataShared data</gtr:partnerContribution><gtr:piContribution>We set up this UK multicentre collaboration which currently includes 10 centres from around the UK</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>MRC Press Release on BMJ paper</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D3A627EA-07BE-4FFD-9407-BFF433C8E5EF</gtr:id><gtr:impact>Media release widely picked up by national print and online media such as BBC News Online, Daily Mail, Nursing Times and others.

Greater awareness of research and screening for oesophageal cancer.</gtr:impact><gtr:outcomeId>YThaApUeJZN</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cambridge Science Festival</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>50F04779-C8A2-45A7-AEFB-626CDB0CA643</gtr:id><gtr:impact>Part of 'Mysterious magic to modern marvels' display at Festival with range of activities for children.

improved awareness of science and research.</gtr:impact><gtr:outcomeId>0AC266E1C28</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>136000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>GSK Project grant</gtr:description><gtr:end>2010-10-02</gtr:end><gtr:fundingOrg>GlaxoSmithKline (GSK)</gtr:fundingOrg><gtr:id>78E4CE71-961C-4265-92A6-04C909DE5C52</gtr:id><gtr:outcomeId>C3FCCEE7B0F0</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2007-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Risk stratification (prediction of likelihood) for progression from Barrett's Esophagus to high grade dysplasia (EAC), using the signature Lectin/DNA content abnormality/CA19-9/CyclinA/p53.</gtr:description><gtr:grantRef>G0601390</gtr:grantRef><gtr:id>3C62F944-3553-4195-B6F1-70475D8244B5</gtr:id><gtr:impact>None to date.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>fuLsAkQGoyr</gtr:outcomeId><gtr:patentId>GB1208756.5</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Risk stratification (prediction of likelihood) for progression from BE to high grade dysplasia (EAC)</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>TIME diagnosis of high grade dysplasia (EAC), using Imaging endoscopy (AFI) plus aneuploidy/p53/cyclinA</gtr:description><gtr:grantRef>G0601390</gtr:grantRef><gtr:id>BADBA185-0354-413C-A5AF-105805E31C86</gtr:id><gtr:impact>None to date</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>cZqaAzyLqex</gtr:outcomeId><gtr:patentId>GB1208963.7</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>TIME diagnosis of high grade dysplasia</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Four gene signature for use in diagnosis of oesophageal cancer.</gtr:description><gtr:grantRef>G0601390</gtr:grantRef><gtr:id>5FD19A55-519C-4630-926A-D55137641CBE</gtr:id><gtr:impact>development for use in screening
PATENT APPLICATION TERMINATED 2011</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>PorXGHXfYDu</gtr:outcomeId><gtr:patentId>GB1005048.2</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Oesophageal prognostic signature</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>The Cytosponge is a cell colection device which when coupled with a molecular marker can be used to diagnose Barrett's oesophagus in the primary care setting</gtr:description><gtr:id>3DFF5B85-FEE4-45E8-9852-FD11BA18F052</gtr:id><gtr:impact>This has now been awarded funding by CRUK for further evaluation in a large-scale clincial trial</gtr:impact><gtr:outcomeId>286964E7402</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Cytosponge</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2008</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A new screening tool was developed and patented which involves a cell collection device suitable for primary care in combination with a molecular marker</gtr:description><gtr:id>4C30214A-7E70-4C56-926F-8B370E4254C1</gtr:id><gtr:impact>PMID: 19651633 [PubMed - in process]</gtr:impact><gtr:outcomeId>BDDA4308EB0</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Cytosponge screening device</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://europepmc.org/abstract/MED/19651633</gtr:url></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>The grant funding covered infrastructure and staff support for the Northern Ireland Population Register of Barrett's oesophagus</gtr:description><gtr:id>6E0D4F8B-E10D-4688-B7C4-DD8A292D873E</gtr:id><gtr:impact>still in progress</gtr:impact><gtr:outcomeId>92D4A6B89A4</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>up to date population based cohort database Barrett's samples</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>8884A45C-23C5-460E-BAB0-5080CD639AC1</gtr:id><gtr:title>Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/10a87656e0db6dfc89344dae8cba6cb4"><gtr:id>10a87656e0db6dfc89344dae8cba6cb4</gtr:id><gtr:otherNames>Kadri SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>GG3GpTZonfJ</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0601390</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>D81A471F-556F-4570-BF6A-5D197943223C</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Oral and Gastrointestinal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>